Duloxetine for Chronic Low Back Pain
Duloxetine 60 mg once daily is effective for chronic low back pain and should be initiated at 30 mg daily for one week before titrating to the target dose of 60 mg daily to minimize gastrointestinal side effects. 1
Evidence Basis and Efficacy
Duloxetine is FDA-approved for chronic musculoskeletal pain, including chronic low back pain, with clinical trial evidence demonstrating statistically significant pain reduction compared to placebo. 1
The 2017 American College of Physicians systematic review found that duloxetine is associated with modest effects for chronic low back pain, representing new evidence that supports its use in this condition. 2
In pivotal trials (CLBP-1 and CLBP-3), duloxetine 60 mg daily produced significantly greater pain reduction than placebo after 12-13 weeks of treatment in patients with baseline pain scores of 6/10. 1
Pain reduction with duloxetine is small to moderate and primarily short-term, with improvements in function generally smaller than pain relief. 2
Duloxetine works for both neuropathic (radicular) and non-neuropathic chronic low back pain, with one crossover trial showing 32% average pain reduction in patients with neuropathic leg pain. 3
Dosing Protocol
Start at 30 mg once daily for 7 days, then increase to 60 mg once daily:
The gradual titration from 30 mg to 60 mg markedly reduces nausea incidence while preserving efficacy, as nausea is dose-dependent and occurs in 24% of patients versus 8% with placebo. 4
There is no evidence that doses higher than 60 mg daily confer additional benefit, and higher dosages (120 mg) are associated with more adverse reactions and premature discontinuations. 1
For patients with inadequate response at 60 mg after 7 weeks who tolerate the medication well, the dose may be increased to 120 mg daily, though this approach showed mixed results in clinical trials. 1
Patient Selection and Monitoring
Appropriate candidates:
- Adults with chronic low back pain (duration >3 months) without signs of radiculopathy or spinal stenosis, or with neuropathic/radicular components. 1, 3
- Baseline pain intensity ≥4 on a 0-10 numerical rating scale. 5
Contraindications and precautions:
- Avoid in patients with chronic liver disease, cirrhosis, or severe renal impairment (GFR <30 mL/min). 1
- Do not use with MAOIs or within 14 days of MAOI discontinuation due to serotonin syndrome risk. 1
Monitoring parameters:
- Assess pain reduction at 4 weeks; patients with ≥30% pain reduction in the first month are more likely to experience sustained long-term benefit. 6
- Monitor for gastrointestinal adverse effects (nausea, dry mouth in 13%, constipation in 10%) which are most common in the first weeks. 4
- Approximately 15% of patients discontinue due to adverse events compared to 5% with placebo, primarily due to nausea. 5
Discontinuation
- Taper gradually rather than stopping abruptly to avoid withdrawal symptoms including dizziness, headache, nausea, paresthesia, and irritability. 1
- Allow at least 5 days after stopping duloxetine before starting an MAOI. 1
Clinical Context
- Duloxetine can be used with or without concurrent NSAID therapy, as subgroup analyses showed no differences in treatment outcomes based on baseline NSAID use. 1
- The medication is particularly useful for patients with mixed nociceptive and neuropathic pain components, as it addresses both mechanisms. 3, 7
- Serious adverse events occur at similar rates to placebo, though total adverse events are higher with duloxetine. 8, 9